- Acid Blockers
Chronic Refractory Cough Market was valued at USD 8982.5 million in 2022 and is poised to grow at a CAGR of 4% over 2023-2029. Chronic refractory cough is defined as a cough that persists despite the guideline-based treatment, and key symptoms include a dry irritated cough localized around the laryngeal region, dyspnea, and dysphonia. Based on the drug class, the combination drugs segment is anticipated to dominate the chronic refractory cough market share over the forecast period. According to an article published in the European Respiratory Journal, the overall prevalence of chronic cough was 9.6%. An increase in the prevalence of conditions such as asthma, bronchitis, GERD, and rising awareness among patients are the chronic refractory cough market growth drivers. However, the side effects associated with the drugs for cough could restrict market growth. Advancements and the use of modern techniques in drug development and diagnosis of the disease could act as opportunities for the players in the market
Fastest Growing Market
Due to rising global healthcare spending and disease awareness, the chronic refractory cough market is expected to witness growth. For instance, the launch of pipeline therapies such as Orvepitant Maleate, BLU-5937, Gefapixant, BAY1817080, and S-600918 will contribute to the market expansion in the upcoming years. Thus, the increased awareness, research, and development for chronic respiratory disorders will lead to the growth of the market within the forecast period. However, the reduced approval rate for drugs will have a negative impact on the market growth.
The Chronic Refractory Cough market was valued at USD 8982.5 million in 2022 and is expected to grow at a 4% CAGR over the forecast period 2023 – 2029.
Advancements and the use of modern techniques in drug development and diagnosis of the disease are the key opportunities for the Chronic Refractory Cough market.
An increase in the prevalence of conditions such as asthma, bronchitis, GERD, and rising awareness among patients are the growth drivers in the Chronic Refractory Cough market.
Merck & Co., GSK PLC, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bayer AG, Shionogi Inc., Avalo Therapeutics, Inc., Aldeyra Therapeutics, Axalbion, and Afferent Pharmaceuticals, Inc. are a few companies operating in the Chronic Refractory Cough market.